A synthetic dextran derivative inhibits complement activation and complement-mediated cytotoxicity in an in vitro model of hyperacute xenograft rejection.
Thomas
H
H
INSERM U430, Hôpital Broussais, Paris, France.
Maillet
F
F
Letourneur
D
D
Jozefonvicz
J
J
Kazatchkine
M D
MD
Fischer
E
E
D000818:Animals; D001011:Aorta; D003167:Complement Activation / Q000187:drug effects*; D015926:Complement C3a / Q000276:immunology; D003179:Complement C3b / Q000276:immunology; D003182:Complement C5 / Q000276:immunology; D015938:Complement Membrane Attack Complex / Q000276:immunology; D003165:Complement System Proteins / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D003911:Dextrans / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology*
D003182:Complement C5; D015938:Complement Membrane Attack Complex; D003911:Dextrans; C099253:CMDBS 25; D015926:Complement C3a; D003179:Complement C3b; D003165:Complement System Proteins